Crenolanib Treatment for FLT3-Mutated AML Blast Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FLT3 inhibitors fail to achieve complete remission in FLT3 mutant AML patients, with bone marrow blasts often remaining unaffected, and there is a need for therapies that can significantly deplete both peripheral blood and bone marrow blasts to improve patient prognosis.
Innovation Solution
Administering crenolanib or its pharmaceutically acceptable salts to patients with FLT3 mutations and additional genetic abnormalities, such as RUNX1, WT1, FLT3-ITD, DNMT3A, and NPM1 mutations, to enhance survival chances by effectively reducing both peripheral blood and bone marrow blasts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current FLT3 inhibitors are administered to FLT3 mutant AML patients, then peripheral blood blasts are reduced, but bone marrow blasts remain unaffected
Solution Approach 1:
The patent employs combination therapy with multiple FLT3 inhibitors (midostaurin and quizartinib) to achieve synergistic effects that overcome resistance mechanisms. This parameter change in treatment approach enables complete remission by simultaneously targeting different aspects of FLT3 signaling pathways, thereby affecting both peripheral blood and bone marrow blasts.
Solution Approach 2:
The invention uses a multi-functional treatment regimen that addresses multiple targets: FLT3 inhibitors for leukemia cells, G-CSF for neutrophil support, and antibiotics for infection prevention. This universal approach simultaneously treats the primary malignancy and manages secondary complications, achieving complete remission while maintaining patient health.
2Reliability
If high doses of FLT3 inhibitors are used to deplete bone marrow blasts, then complete remission may be achieved, but toxicity and side effects increase
Solution Approach 1:
The treatment protocol dynamically adjusts FLT3 inhibitor dosing based on patient response and tolerance. The regimen alternates between intensive therapy phases targeting bone marrow blasts and recovery phases allowing bone marrow repopulation, thereby achieving complete remission while minimizing cumulative toxicity through adaptive dose modification.
Solution Approach 2:
The invention implements periodic cycles of intensive FLT3 inhibitor therapy followed by recovery intervals with supportive care. This periodic action pattern allows the bone marrow to partially recover between treatment intensification phases, reducing cumulative toxicity while maintaining efficacy in depleting residual leukemia cells.
3Reliability
If combination therapy with multiple FLT3 inhibitors is administered, then complete remission is achieved, but treatment complexity increases
Solution Approach 1:
The treatment protocol maintains continuous therapeutic pressure on FLT3-positive leukemia cells through overlapping administration of midostaurin and quizartinib with different pharmacokinetic profiles. This continuous action ensures complete remission by preventing escape mechanisms while the structured schedule manages treatment complexity through predictable dosing intervals.
Data Source
AI summary
The present invention includes methods for treating a FLT3 mutated proliferative disorder comprising: measuring expression of a mutated FLT3 and one or more genetic abnormalities in a sample obtained from a tumor sample obtained from the patient, wherein the presence of the one or more genetic abnormalities indicates that the patient has a poor prognosis; and administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof, wherein the crenolanib increases a chance of survival of the patient having both the mutated FLT3 and the one or more genetic abnormalities, wherein the crenolanib, as shown below, is administered to a subject suffering from said disorder: